Trailblazing TRAIL Therapy: Illuminating Pathways for Cholangiocarcinoma Treatment

Article Properties
Cite
Ko, Sungjin. “Trailblazing TRAIL Therapy: Illuminating Pathways for Cholangiocarcinoma Treatment”. Cellular and Molecular Gastroenterology and Hepatology, vol. 17, no. 5, 2024, pp. 885-6, https://doi.org/10.1016/j.jcmgh.2024.02.008.
Ko, S. (2024). Trailblazing TRAIL Therapy: Illuminating Pathways for Cholangiocarcinoma Treatment. Cellular and Molecular Gastroenterology and Hepatology, 17(5), 885-886. https://doi.org/10.1016/j.jcmgh.2024.02.008
Ko S. Trailblazing TRAIL Therapy: Illuminating Pathways for Cholangiocarcinoma Treatment. Cellular and Molecular Gastroenterology and Hepatology. 2024;17(5):885-6.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the digestive system
Gastroenterology
Medicine
Medicine (General)
Refrences
Title Journal Journal Categories Citations Publication Date
Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma Cellular and Molecular Gastroenterology and Hepatology
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Medicine (General)
 1 2024
Immunobiology of cholangiocarcinoma Journal of Hepatology
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine
  • Medicine: Medicine (General)
 10 2023
6-Methoxydihydrosanguinarine exhibits cytotoxicity and sensitizes TRAIL-induced apoptosis of hepatocellular carcinoma cells through ROS-mediated upregulation of DR5 Medical Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1 2023
Cholangiocarcinoma — novel biological insights and therapeutic strategies Nature Reviews Clinical Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 23 2023
TRAIL in combination with subtoxic 5-FU effectively inhibit cell proliferation and induce apoptosis in cholangiocarcinoma cells 2015
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)2
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology2
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens1
Medicine1
The category Medicine: Medicine (General) 2 is the most frequently represented among the references in this article. It primarily includes studies from Nature Reviews Clinical Oncology and Gastroenterology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year